Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

kemofarmacija d.d. - metformin - tableta s podaljšanim sproščanjem - metformin 1000 mg / 1 tableta - metformin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

kemofarmacija d.d. - metformin - tableta s podaljšanim sproščanjem - metformin 390 mg / 1 tableta - metformin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

sandoz d.d. - metformin; vidagliptin - filmsko obložena tableta - metformin 660 mg / 1 tableta  vidagliptin50 mg / 1 tableta; vidagliptin 50 mg / 1 tableta - metformin in vildagliptin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

sandoz d.d. - metformin, vidagliptin - filmsko obložena tableta - metformin 780 mg / 1 tableta; vidagliptin 50 mg / 1 tableta - metformin in vildagliptin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

sandoz d.d. - metformin; vidagliptin - filmsko obložena tableta - metformin 780 mg / 1 tableta  vidagliptin50 mg / 1 tableta; vidagliptin 50 mg / 1 tableta - metformin in vildagliptin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

sandoz d.d. - metformin; vidagliptin - filmsko obložena tableta - metformin 660 mg / 1 tableta  vidagliptin50 mg / 1 tableta; vidagliptin 50 mg / 1 tableta - metformin in vildagliptin

Evropska unija - slovenščina - EMA (European Medicines Agency)

janssen-cilag international nv - canagliflozin, metformin hidroklorid - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - vokanamet je navedeno pri odraslih, starih 18 let in več, z vrsto 2 sladkorna bolezen kot dodatek k prehrani in vadbi za izboljšanje glycaemic nadzor:pri bolnikih, ki ni ustrezno nadzorovana na njihovo maksimalno dopustne koncentracije metforminom alonein bolnikov na njihovo maksimalno dopustne koncentracije metforminom skupaj z drugimi glukoze znižanje medicini, vključno z insulina, ko te ne zagotavljajo ustrezne glycaemic nadzor. pri bolnikih, ki se že zdravijo z kombinacijo canagliflozin in metforminom kot ločene tabletsfor študijski rezultati glede kombinacija terapij, vplivi na glycaemic nadzor in srčno-žilne dogodke, in populacije, ki je študiral glej poglavji 4. 4, 4. 5 in 5.

Evropska unija - slovenščina - EMA (European Medicines Agency)

takeda pharma a/s - alogliptin benzoata, metformin hidroklorid - diabetes mellitus, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - vipdomet is indicated in the treatment of adult patients aged 18 years and older with type-2 diabetes mellitus:as an adjunct to diet and exercise to improve glycaemic control in adult patients, inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of alogliptin and metformin;in combination with pioglitazone (i. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and pioglitazone;in combination with insulin (i. trojna kombinacija terapija), kot dodatek k prehrani in vadbi za izboljšanje glycaemic nadzor pri bolnikih, pri insulina na stabilen odmerek in metforminom sam ne zagotavljajo ustrezne glycaemic nadzor.

Evropska unija - slovenščina - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 in 5. 1 za razpoložljive podatke o različnih kombinacijah).

Evropska unija - slovenščina - EMA (European Medicines Agency)

accord healthcare s.l.u. - sitagliptin hydrochloride - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.